Finoriq research workspace
AGIOS PHARMACEUTICALS, INC. (AGIO) SEC Filings & Filing Highlights
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the. Review AGIO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Company
- AGIOS PHARMACEUTICALS, INC. (AGIO)
- Ticker
- AGIO
- Market Cap
- $2.4B
- Latest Price
- $40.25
- Industry
- Biotech & Pharma
AGIOS PHARMACEUTICALS, INC. (AGIO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AGIOS PHARMACEUTICALS, INC. (AGIO).
| Event | Form | Date |
|---|---|---|
| The following is a summary of the matters voted on at the Annual MeetingThe following is a summary of the matters voted on at the Annual Meeting | 8-K5.07 | 2026-06-18 |
| At the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “Company”) held...At the 2026 Annual Meeting of Stockholders of Agios Pharmaceuticals, Inc. (the “Company”) held on June 18, 2026 (the “Annual Meeting”), the... | 8-K5.02 | 2026-06-18 |
| Agios Reports First Quarter 2026 Financial Results and Provides Business UpdateAgios Reports First Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-04-29 |
| Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateAgios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 8-K2.02 | 2026-02-12 |
| Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfoli...Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth | 8-K7.01 | 2026-01-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.